Dynamics (NASDAQ:DYNS) announced in an 8-K filing this afternoon that its shareholders have voted to approve its combination with Gene Circuit company Senti Biosciences in a special meeting held earlier today.
Holders of 14,549,537 shares of Class A common stock elected to redeem their public shares resulting in 63.259% of Dynamic’s trust being removed. DYNS had previously secured a non-redemption agreement with a number of institutional investors including Morgan Stanley Investment Management Inc., T. Rowe Price Group, Inc., The Invus Group, LLC and ARK Investment Management LLC. Each of these investors agreed not to redeem their shares at the combination vote.
As background, Dynamics brought $230 million into the deal, which it supplemented with a $66.8 million PIPE at $10 per share. The PIPE drew investment from healthcare and technology investors, including 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global, Invus, LifeForce Capital, NEA, Parker Institute for Cancer Immunotherapy, T. Rowe Price Associates, and others.
The deal is expected to close tomorrow, June 8, and the combined company is expected to trade on the Nasdaq.
Dynamics initially announced the $276 million combination with Senti BioSciences on December 20, 2021. San Francisco-based Senti Bio uses its Gene Circuit platform to develop next-generation cell and gene therapies to enhance therapeutic effectiveness against diseases.
At the special meeting, the company’s stockholders also approved, among other items, the New Senti 2022 Equity Incentive Plan and the New Senti 2022 Employee Stock Purchase Plan.
ADVISORS
- J.P. Morgan is acting as lead capital markets advisor to Dynamics and co-placement agent for the PIPE.
- Morgan Stanley & Co. LLC is acting as financial advisor to Dynamics and co-placement agent to Dynamics for the PIPE.
- BofA Securities is acting as exclusive financial advisor to Senti Bio and as co-placement agent for the PIPE.
- Davis Polk & Wardwell LLP is serving as legal advisor to Dynamics.
- Goodwin Procter LLP is serving as legal advisor to Senti Bio
- Latham & Watkins LLP is serving as legal advisor to J.P. Morgan
- Morgan Stanley & Co. LLC and BofA Securities in their role as placement agents
Terms Tracker for the Week Ending December 20, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. * We will be skipping next week’s Terms Tracker post while we work on putting together our “2024 Year End Review”. You can find 2023’s...
Four Leaf Acquisition Corporation (NASDAQ:FORL) has entered into a definitive agreement to combine with Chinese technology firm Xiaoyu Dida for undisclosed terms. The Guangzhou, China-based firm produces software and hardware for smart car washing systems. The parties have set December 31, 2025 as the initial outside date and the combined company is expected to trade...
At the SPAC of Dawn SPACs are back on the board with a new deal announcement, which is the first in a little over two weeks. This brings the fourth quarter count on fresh deals to a still-meager nine after 27 were announced in the third quarter. By contrast, this quarter has still seen more...
Range Capital Acquisition Corp. (NASDAQ: RANGU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “RANGU”, Friday, December 20, 2024. The new SPAC intends to take a generalist approach in searching for a business combination, but will seek opportunities in capital constrained...
SPAC Deja Vu There’s been a lot of talk this year in the SPAC market about how it’s finally reverting back to a healthier version of deal flow and the comparison is always, “….like 2019”. In fact, in 2019, Trump was in office and there were 59 SPAC IPOs priced. As of this morning, Trump...